-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

Benzinga·10/07/2026 14:33:50
Listen to the news
Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.